Literature DB >> 3528148

Preproglucagon gene expression in pancreas and intestine diversifies at the level of post-translational processing.

S Mojsov, G Heinrich, I B Wilson, M Ravazzola, L Orci, J F Habener.   

Abstract

Glucagon is a pancreatic hormone of 29 amino acids that regulates carbohydrate metabolism and glicentin is an intestinal peptide of 69 amino acids that contains the sequence of glucagon flanked by peptide extensions at the amino and carboxy termini. The glucagon gene encodes a precursor containing glucagon and two additional, structurally related, glucagon-like peptides separated by an intervening peptide. These peptides are encoded in separate exons. To determine whether the pancreatic and intestinal forms of glucagon arise by alternative RNA and/or protein processing, we used antisera to synthetic glucagon-like peptides and exon-specific, complementary oligonucleotides for analyses of proteins and mRNAs in pancreatic and intestinal extracts. Preproglucagon mRNAs are identical, but different and highly specific peptides are liberated in the two tissues. Immunocytochemistry shows colocalization of glucagon and the two glucagon-like peptides in identical cells. We conclude that diversification of preproglucagon gene expression occurs at the level of cell-specific post-translational processing.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3528148

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  140 in total

Review 1.  Gut adaptation and the glucagon-like peptides.

Authors:  D J Drucker
Journal:  Gut       Date:  2002-03       Impact factor: 23.059

Review 2.  Type 2 diabetes mellitus: a possible surgically reversible intestinal dysfunction.

Authors:  Priscila C Sala; Raquel S Torrinhas; Steven B Heymsfield; Dan L Waitzberg
Journal:  Obes Surg       Date:  2012-01       Impact factor: 4.129

Review 3.  Bowels control brain: gut hormones and obesity.

Authors:  Benjamin C T Field; Owais B Chaudhri; Stephen R Bloom
Journal:  Nat Rev Endocrinol       Date:  2010-06-29       Impact factor: 43.330

Review 4.  The structure and function of the glucagon-like peptide-1 receptor and its ligands.

Authors:  Dan Donnelly
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

Review 5.  The insulin secretory granule.

Authors:  J C Hutton
Journal:  Diabetologia       Date:  1989-05       Impact factor: 10.122

Review 6.  Glucagon-like peptide 1 (GLP-1).

Authors:  T D Müller; B Finan; S R Bloom; D D'Alessio; D J Drucker; P R Flatt; A Fritsche; F Gribble; H J Grill; J F Habener; J J Holst; W Langhans; J J Meier; M A Nauck; D Perez-Tilve; A Pocai; F Reimann; D A Sandoval; T W Schwartz; R J Seeley; K Stemmer; M Tang-Christensen; S C Woods; R D DiMarchi; M H Tschöp
Journal:  Mol Metab       Date:  2019-09-30       Impact factor: 7.422

Review 7.  The role of incretins in glucose homeostasis and diabetes treatment.

Authors:  Wook Kim; Josephine M Egan
Journal:  Pharmacol Rev       Date:  2008-12-12       Impact factor: 25.468

8.  Different domains of the glucagon and glucagon-like peptide-1 receptors provide the critical determinants of ligand selectivity.

Authors:  S Runge; B S Wulff; K Madsen; H Bräuner-Osborne; L B Knudsen
Journal:  Br J Pharmacol       Date:  2003-03       Impact factor: 8.739

9.  Inhibitory effect of glucagon-like peptide-1 on small bowel motility. Fasting but not fed motility inhibited via nitric oxide independently of insulin and somatostatin.

Authors:  T Tolessa; M Gutniak; J J Holst; S Efendic; P M Hellström
Journal:  J Clin Invest       Date:  1998-08-15       Impact factor: 14.808

10.  Agonist-induced internalization and recycling of the glucagon-like peptide-1 receptor in transfected fibroblasts and in insulinomas.

Authors:  C Widmann; W Dolci; B Thorens
Journal:  Biochem J       Date:  1995-08-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.